Gary L. Crocker is the Managing Director of Crocker Ventures, LLC, a privately held life science and high technology investment firm. Since 2004 he has also served as Chairman of Merrimack Pharmaceuticals, a personalized oncology drug development firm. He has held senior executive or board director level positions in several prominent life science and technology firms, including: Chairman of ARUP Laboratories; director of Interleukin Genetics, and LineaGen Genetics; co-founder and director of Theratech Pharma (acquired by Watson Pharmaceuticals in 1999), and Vice President of Marketing for the Critical Care Products Division of Abbott Laboratories. He is currently the Chairman and sole investor in three orthopedic medical device firms, Nexus CMF, LLC, Nexus Spine, LLC and Nexus, TDR Inc (an artificial back disc firm).
In 1983, Crocker founded Research Medical, and was the Chairman and CEO of this publicly held manufacturer and marketer of specialty open heart surgery catheters until the sale of the firm to Baxter International’s Edwards Laboratories division in 1997 for $236 million, at that time the largest medical device merger in state history. He has been selected twice as Utah Entrepreneur of the Year by both Ernst and Young and the MountainWest Capital Network. He earned his MBA and also graduated magna cum laude with a bachelor’s degree in economics from Harvard University.
